Post A Reply
my profile
login
|
register
|
search
|
faq
|
forum home
»
Allstocks.com's Bulletin Board
»
.11 and Up!
»
CTIX -- Cellceutix Corporation
» Post A Reply
Post A Reply
Login Name:
Password:
Message Icon:
Message:
HTML is enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by BooDog: [QB] CTIX May 21st “Understanding QIDP and Other 21st Century Incentives for Developing and Marketing Anti-Infective Medicines,” on May 21, 2015 at the New York Palace Hotel. This investor event will be focused on the positive impact of the GAIN Act and the QIDP designation on investments in companies with anti-infective programs. The event is designed to help investors understand how leveraging various regulatory and commercial incentives translate to increased shareholder value. Speakers will include regulatory attorneys, legislators, industry executives and medical professionals. Investors interested in attending should contact Tirth Patel of Tiberend Strategic Advisors, Inc.: tpatel@tiberend.com. To access the webcast go to: http://psav.rampard.com/20150521/ web cast sponsored by Cellceutix, CoreMedix & NEXGEN Biosciences. starts 8am 5/21/15 webcast link http://psav.rampard.com/20150521/reg.jsp [URL=http://50.87.248.71/~cormedix/wp-content/uploads/2014/11/QIDP-Formal-Invite-2-435x1024.jpg]http://50.87.248.71/~cormedix/wp-content/uploads/2014/11/QIDP-Formal-Invite-2-43 5x1024.jpg[/URL] ============================================== Posted by 'farrell90'... Power point presentation on CTIX web page. [URL=http://cellceutix.com/wp-content/uploads/2014/06/QIDP_21May2015-Power-Point-Presentation.pdf]http://cellceutix.com/wp-content/uploads/2014/06/QIDP_21May2015-Power-Point-Pres entation.pdf[/URL] Recounts Brilacidin information previously released. Gram negative drug has the potential to be another big winner,CC-1807 New information regarding the gram negative drug: CC-1807 being optimized for urinary tract infections, bacteremia and lung infections {pneumonia} Optimized for expanded Gram neg coverage to include Pseudomonas and Acineobacter From power point: Gram-negative activity evident in several structural series of small nonpeptidic mimetics of host defense proteins 2 series show low cytotoxicity, favorable PK properties and robust efficacyin vitro and in vivo against Enterobacteriaceae organisms CC-1807 is potently active against clinical isolates of E. coli, K. pneumoniae and E. cloacae, including MDR CRE strains Additional preclinical efficacy studies with CC-1807 are in progress Dose optimization in lung infection models UTI and bacteremia Chemical optimization of CC-1807 and additional analogs is continuing Expand coverage to Pseudomonas and Acinetobacter spp =================================================== [/QB][/QUOTE]
Instant Graemlins
Instant UBB Code™
What is UBB Code™?
Options
Disable Graemlins in this post.
*** Click here to review this topic. ***
Contact Us
|
Allstocks.com Message Board Home
© 1997 - 2021 Allstocks.com. All rights reserved.
Powered by
Infopop Corporation
UBB.classic™ 6.7.2